Cost-Effectiveness and the Economics of Genomic Testing and Molecularly Matched Therapies

Surg Oncol Clin N Am. 2024 Apr;33(2):231-242. doi: 10.1016/j.soc.2023.12.010. Epub 2024 Jan 27.ABSTRACTCost-effectiveness analysis of precision oncology can help guide value-driven care. Next-generation sequencing is increasingly cost-efficient over single gene testing because diagnostic algorithms require multiple individual gene tests to determine biomarker status. Matched targeted therapy is often not cost-effective due to the high cost associated with drug treatment. However, genomic profiling can promote cost-effective care by identifying patients who are unlikely to benefit from therapy. Additional applications of genomic profiling such as universal testing for hereditary cancer syndromes and germline testing in patients with cancer may represent cost-effective approaches compared with traditional history-based diagnostic methods.PMID:38401907 | DOI:10.1016/j.soc.2023.12.010

Source: Clinical Colorectal Cancer - February 24, 2024 Category: Cancer & Oncology Authors: Sudeep Banerjee Source Type: research